Expression of Hematopoietic Stem and Endothelial Cell Markers in Canine Hemangiosarcoma

• Published in: Toxicologic pathology Vol. 48; no. 3; p. 481
• Main Authors: Kakiuchi-Kiyota, Satoko, Obert, Leslie A, Crowell, Danielle M, Xia, Shuhua, Roy, Marc D, Coskran, Timothy M, Kreeger, John M, Crabbs, Torrie A, Cohen, Samuel M, Cattley, Russell C, Cook, Jon C
• Format: Journal Article
• Language: English
• Published: United States 01.04.2020
• Subjects: canine; immunohistochemistry; hematopoietic stem cells; endothelial progenitor cells; tumor; hemangiosarcoma
• DOI: 10.1177/0192623319897539

Several chemicals and pharmaceuticals increase the incidence of hemangiosarcomas (HSAs) in mice, but the relevance to humans is uncertain. Recently, canine HSAs were identified as a powerful tool for investigating the pathogenesis of human HSAs. To characterize the cellular phenotype of canine HSAs, we evaluated immunoreactivity and/or messenger RNA (mRNA) expression of markers for hematopoietic stem cells (HSCs), endothelial cells (ECs), a tumor suppressor protein, and a myeloid marker in canine HSAs. Neoplastic canine cells expressed EC markers and a myeloid marker, but expressed HSC markers less consistently. The canine tumor expression results were then compared to previously published immunoreactivity results for these markers in human and mouse HSAs. There are 2 noteworthy differences across species: (1) most human HSAs had HSC marker expression, indicating that they were comprised of tumor cells that were less differentiated than those in canine and mouse tumors; and (2) human and canine HSAs expressed a late-stage EC maturation marker, whereas mouse HSAs were negative, suggesting that human and canine tumors may retain greater differentiation potential than mouse tumors. These results indicate that HSA development is variable across species and that caution is necessary when discussing translation of carcinogenic risk from animal models to humans.